Lysosomal Fusion: An Efficient Mechanism Increasing Their Sequestration Capacity for Weak Base Drugs without Apparent Lysosomal Biogenesis
Lysosomal sequestration of anticancer therapeutics lowers their cytotoxic potential, reduces drug availability at target sites, and contributes to cancer resistance. Only recently has it been shown that lysosomal sequestration of weak base drugs induces lysosomal biogenesis mediated by activation of...
Main Authors: | Nikola Skoupa, Petr Dolezel, Petr Mlejnek |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/1/77 |
Similar Items
-
The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance
by: Eliska Ruzickova, et al.
Published: (2019-10-01) -
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
by: Kaamar Azijli, et al.
Published: (2016-01-01) -
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
by: Maria Krchniakova, et al.
Published: (2020-04-01) -
Better Together: Current Insights Into Phagosome-Lysosome Fusion
by: Jenny A. Nguyen, et al.
Published: (2021-02-01) -
Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
by: Bernhard Englinger, et al.
Published: (2018-12-01)